HIV post exposure prophylaxis induced bicytopenia: a case report

AIDS Research and Therapy

Mathias W Pletz²  Stefan Hagel²  Peter M Keller¹  John P Fobiwe³  Benjamin T Schleenvoigt¹ 

[1]Institute for Medical Microbiology, Jena University Hospital, Jena, Germany

[2]Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany

[3]Center for Infectious Diseases and Infection Control, Jena University Hospital, Erlanger Allee 101, Jena, Thuringia 07740, Germany

关键词: Ritonavir;    Lopinavir;    Emtricitabin;    Tenofovir;    Thrombocytopenia;    Leukopenia;    Post exposure prophylaxis;    HIV;   

Others  :  789539
DOI  :  10.1186/1742-6405-11-11

 received in 2013-11-05, accepted in 2014-02-01,  发布年份 2014

【 摘 要 】

Long and short term side effects of antiretroviral drugs are not fully understood yet. Here a case of reversible blood count changes following post exposure prophylaxis with tenofovir/emtricitabin and lopinavir/ritonavir is reported. We propose that antiretroviral drugs used in post exposure prophylaxis may have a significant impact on hematopoiesis.

【 授权许可】

   
2014 Schleenvoigt et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Gemeinsame Erklarung der Deutschen A-G: Post-exposure prophylaxis of HIV infection. German-Austrian recommendations, update September 2007. Dtsch Med Wochenschr 2009, 134(Suppl 1):S16-33.
• [2]Guidelines Version 7.0 October 2013 http://www.eacsociety.org webcite
• [3]Choi SY, Kim I, Kim NJ, Lee SA, Choi YA, Bae JY, Kwon JH, Choe PG, Park WB, Yoon SS, et al.: Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia. Korean J Hematol 2011, 46:253-257.
• [4]Alp E, Bozkurt I, Doganay M: Epidemiological and clinical characteristics of HIV/AIDS patients followed-up in Cappadocia region: 18 years experience. Mikrobiyol Bul 2011, 45:125-136.
• [5]Colebunders R, De Schacht C, Vanwolleghem T, Callens S: Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection. Int J Infect Dis 2004, 8:315-316.
• [6]Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, et al.: Prevalence of adverse events associated with potent antiretroviral treatment: swiss HIV cohort study. Lancet 2001, 358:1322-1327.